Skip to main content

Osteoporosis in Post-menopausal Women

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
Human Umbilical Cord-derived Mesenchymal stem cellPHASE_11 trial
Active Trials
NCT06949137Active Not Recruiting9Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2025
2026
HELP TherapeuticsHuman Umbilical Cord-derived Mesenchymal stem cell

Clinical Trials (1)

Total enrollment: 9 patients across 1 trials

NCT06949137HELP TherapeuticsHuman Umbilical Cord-derived Mesenchymal stem cell

Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Start: Jun 2025Est. completion: Sep 20269 patients
Phase 1Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.